The European Patent Office (EPO) has published patent application EP4512801A1, filed by Kissei Pharmaceutical Co., Ltd., for a novel 3,4-dihydroquinolin-2(1H)-one compound. The publication date is March 11, 2026, and it includes International Patent Classification (IPC) codes related to organic chemistry and pharmaceutical applications, such as C07D 215/24 and A61K 31/4704.

This publication represents the grant of a patent for a specific chemical compound and its potential therapeutic uses. While this is a patent publication and not a regulatory rule, it signifies intellectual property protection for Kissei Pharmaceutical. Compliance officers in the pharmaceutical sector should note this patent as it may affect the freedom to operate for other entities developing similar compounds or seeking to market related products within the designated European states.